Wednesday, July 8, 2026

Patent intelligence · US

US 11786536

Salts of potassium ATP channel openers and uses thereof

granted A61KA61K31/54A61K31/549A61K38/27
Status granted
Linked drugs 3
Pipeline programs 3
Years to expiry 17
Applicant portfolio 95
Patent details — US 11786536
Jurisdiction
US
Status
granted
Grant date
Oct 17, 2023
Expiration
Oct 12, 2043
Applicant
ESSENTIALIS, INC.
Claims
8
CPC classes
A61K, A61K31/54, A61K31/549, A61K38/27
View on Google Patents ↗

Quick answer

US 11786536 (Salts of potassium ATP channel openers and uses thereof) is held by ESSENTIALIS, INC.. Status: granted. Granted Oct 17, 2023. Expires Oct 12, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
ESSENTIALIS, INC.
Grant date
Expiration
Claims
8
CPC classes
A61K, A61K31/54, A61K31/549, A61K38/27, A61K45/06, A61K9/2086

More from ESSENTIALIS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12419895

    Methods for treating subjects with Prader-Willi syndrome

    ESSENTIALIS, INC. · Expires Sep 18, 2045

    granted
  2. US 12350258

    Compositions and methods for treatment of skin-related diseases and promoting dermatological health

    Script Essentials, LLC · Expires Jul 3, 2045

    granted
  3. US 12343348

    Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

    ESSENTIALIS, INC. · Expires Jun 26, 2045

    granted
  4. US 12343381

    Dosage regimen for pegylated interferon

    PHARMAESSENTIA CORPORATION · Expires Jun 26, 2045

    granted
  5. US 12178823

    Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

    ESSENTIALIS, INC. · Expires Dec 26, 2044

    granted
  6. US 12109216

    Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

    ESSENTIALIS, INC. · Expires Oct 3, 2044

    granted
  7. US 12005081

    Chimeric receptors and methods of use thereof

    Senti Biosciences, Inc. · Expires Jun 6, 2044

    granted
  8. US 11884656

    Pyrrole derivatives as PLK1 inhibitors

    SENTINEL ONCOLOGY LIMITED · Expires Jan 25, 2044

    granted

Frequently asked questions

What is US patent 11786536?

US 11786536 (Salts of potassium ATP channel openers and uses thereof) is held by ESSENTIALIS, INC.. Status: granted. Granted Oct 17, 2023. Expires Oct 12, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11786536?

ESSENTIALIS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.

When does US 11786536 expire?

Our index shows an expiration date of Oct 12, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.